Pharma Products Face Uncertain Future In Boston Scientific's 'Logical' £3.3bn Bid For UK's BTG

 
• By Sten Stovall

Boston Scientific CEO says US group has been tracking UK-based BTG "for more than two years" and that interventional medicine is a key attraction.

IT transaction or merger between companies
BTG Board Has Recommended Boston Scientific's 840p/share cash offer • Source: Shutterstock

More from Deals

More from Business